SG11202103756XA - Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells - Google Patents
Extracellular vesicles for targeted therapies against myeloid-derived suppressor cellsInfo
- Publication number
- SG11202103756XA SG11202103756XA SG11202103756XA SG11202103756XA SG11202103756XA SG 11202103756X A SG11202103756X A SG 11202103756XA SG 11202103756X A SG11202103756X A SG 11202103756XA SG 11202103756X A SG11202103756X A SG 11202103756XA SG 11202103756X A SG11202103756X A SG 11202103756XA
- Authority
- SG
- Singapore
- Prior art keywords
- extracellular vesicles
- targeted therapies
- suppressor cells
- derived suppressor
- therapies against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862747982P | 2018-10-19 | 2018-10-19 | |
PCT/US2019/057043 WO2020082005A2 (en) | 2018-10-19 | 2019-10-18 | Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202103756XA true SG11202103756XA (en) | 2021-05-28 |
Family
ID=70283167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202103756XA SG11202103756XA (en) | 2018-10-19 | 2019-10-18 | Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210332386A1 (en) |
EP (1) | EP3850104A4 (en) |
JP (1) | JP2022505159A (en) |
KR (1) | KR20210081362A (en) |
CN (1) | CN113286826A (en) |
AU (1) | AU2019362064A1 (en) |
BR (1) | BR112021007287A2 (en) |
CA (1) | CA3116886A1 (en) |
IL (1) | IL282405A (en) |
MX (1) | MX2021004470A (en) |
SG (1) | SG11202103756XA (en) |
WO (1) | WO2020082005A2 (en) |
ZA (1) | ZA202102404B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220148567A (en) * | 2021-04-29 | 2022-11-07 | 주식회사 서지넥스 | Hepatocellular carcinoma specific targeting exosome composition as a drug anticancer delivery and use thereof |
KR102620197B1 (en) * | 2021-04-30 | 2024-01-02 | 가톨릭대학교 산학협력단 | Colorectal cancer specific targeting exosome composition as a drug anticancer delivery and use thereof |
KR102632530B1 (en) * | 2021-05-24 | 2024-02-02 | 가톨릭대학교 산학협력단 | Stomach cancer specific targeting exosome composition as a drug anticancer delivery and use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011097480A1 (en) * | 2010-02-05 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
US10308959B2 (en) * | 2013-01-18 | 2019-06-04 | Henry Ford Health System | Methods, systems, and compositions relating to MiRNA-146a |
WO2015002956A1 (en) * | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
EP3753552A1 (en) * | 2014-12-03 | 2020-12-23 | Capricor, Inc. | Processes for producing stable exosome formulations |
WO2016179417A2 (en) * | 2015-05-06 | 2016-11-10 | The University Of Utah Research Foundation | Exosome delivery of micrornas |
GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
GB201809622D0 (en) * | 2018-06-12 | 2018-07-25 | Evox Therapeutics Ltd | Engineering extracellular vesicles for affinity purification |
-
2019
- 2019-10-18 SG SG11202103756XA patent/SG11202103756XA/en unknown
- 2019-10-18 MX MX2021004470A patent/MX2021004470A/en unknown
- 2019-10-18 KR KR1020217014377A patent/KR20210081362A/en active Search and Examination
- 2019-10-18 AU AU2019362064A patent/AU2019362064A1/en active Pending
- 2019-10-18 BR BR112021007287-0A patent/BR112021007287A2/en unknown
- 2019-10-18 EP EP19873830.4A patent/EP3850104A4/en active Pending
- 2019-10-18 CN CN201980080032.8A patent/CN113286826A/en active Pending
- 2019-10-18 US US17/284,284 patent/US20210332386A1/en active Pending
- 2019-10-18 JP JP2021521099A patent/JP2022505159A/en active Pending
- 2019-10-18 CA CA3116886A patent/CA3116886A1/en active Pending
- 2019-10-18 WO PCT/US2019/057043 patent/WO2020082005A2/en unknown
-
2021
- 2021-04-13 ZA ZA2021/02404A patent/ZA202102404B/en unknown
- 2021-04-18 IL IL282405A patent/IL282405A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3850104A2 (en) | 2021-07-21 |
EP3850104A4 (en) | 2022-07-06 |
BR112021007287A2 (en) | 2021-07-27 |
WO2020082005A3 (en) | 2020-07-30 |
CA3116886A1 (en) | 2020-04-23 |
WO2020082005A2 (en) | 2020-04-23 |
MX2021004470A (en) | 2021-09-14 |
JP2022505159A (en) | 2022-01-14 |
CN113286826A (en) | 2021-08-20 |
AU2019362064A1 (en) | 2021-05-20 |
IL282405A (en) | 2021-06-30 |
KR20210081362A (en) | 2021-07-01 |
ZA202102404B (en) | 2022-10-26 |
US20210332386A1 (en) | 2021-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277344A (en) | Extracellular vesicles comprising sting-agonist | |
EP3661556A4 (en) | Synthetic extracellular vesicles for novel therapies | |
MA50086A (en) | BACTERIAL EXTRACELLULAR (EV) VESICLES | |
IL282405A (en) | Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells | |
ZA202102016B (en) | Combination therapies | |
HK1247964A1 (en) | Extracellular vesicles for agent delivery | |
NO20171690A1 (en) | Fire extinguisher cover for electric vehicle | |
IL246997A0 (en) | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) | |
MX2017001079A (en) | Bcma chimeric antigen receptors. | |
IL280658A (en) | Extracellular vesicles for inhalation | |
EP3660142A4 (en) | Method for isolating extracellular vesicles using cations | |
PL3576241T3 (en) | Battery system | |
IL305753A (en) | Extracellular vesicles from stem cells | |
ZA202102015B (en) | Combination therapies | |
ZA202102727B (en) | Immunoablative therapies | |
GB2589473B (en) | 2-slot inline block manifold system | |
SG11202102688PA (en) | Surface modified extracellular vesicles | |
EP3765862C0 (en) | Battery monitor control system | |
GB201915855D0 (en) | An extracellular vesicle | |
GB2604071B (en) | New framework for few-shot temporal action localization | |
GB201812371D0 (en) | Battery monitor | |
IL280851A (en) | Target-specific extracellular vesicles | |
IL287370A (en) | Extracellular vesicles derived from activated car-t cells | |
GB201612204D0 (en) | Method for temporal inter-view prediction and technical equipment for the same | |
EP3215877A4 (en) | Electro-optically based network infrastructures for telecommunication systems |